Catalent (CTLT) Tops Q1 EPS by 5c, Revenues Beat; Raises FY21 Revenue Guidance Above Consensus
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Catalent, Inc. Reports First Quarter Fiscal 2021 Results
November 3, 2020 7:15 AM ESTÂ Q1'21 net revenue of $845.7 million increased 27% as-reported, or 26% in constant currency, compared to Q1'20. On an organic basis, constant currency net revenue in Q1'21 grew 20% compared to Q1'20. Â Q1'21 Adjusted EBITDA of $174.4 million increased 37% as-reported, or 35% in constant currency, compared to Q1'20. Q1'21 Biologics segment net revenue of $377.1 million doubled compared to Q1'20. Net debt leverage of 2.6x as of September 30; more than $1 billion in cash and cash equivalents on-hand at September 30. Increased... More
